Overview

  • Product nameAnti-GTPase HRAS antibody
    See all GTPase HRAS primary antibodies
  • Description
    Rabbit polyclonal to GTPase HRAS
  • Tested applicationsSuitable for: WB, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide, corresponding to a region within amino acids 111-176 of GTPase HRAS (NP_005334).

  • Positive control
    • 293T, A431, HeLa, HepG2 and MOLT4 cell lysates for WB; HeLa cells for ICC/IF; OVCAR3 xenograft for IHC-P

Properties

Applications

Our Abpromise guarantee covers the use of ab97488 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 21 kDa.
IHC-P 1/100 - 1/500.
ICC/IF 1/100 - 1/200.

Target

  • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
  • Post-translational
    modifications
    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links
  • Alternative names
    • C BAS/HAS antibody
    • c H ras antibody
    • C HA RAS1 antibody
    • c has/bas p21 protein antibody
    • c ras Ki 2 activated oncogene antibody
    • c-H-ras antibody
    • CTLO antibody
    • GTP and GDP binding peptide B antibody
    • GTPase HRas, N-terminally processed antibody
    • H Ras 1 antibody
    • H RASIDX antibody
    • H-Ras-1 antibody
    • Ha Ras antibody
    • Ha Ras1 proto oncoprotein antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • Harvey rat sarcoma viral oncogene homolog antibody
    • Harvey rat sarcoma viral oncoprotein antibody
    • HRAS antibody
    • HRAS1 antibody
    • K ras antibody
    • N ras antibody
    • p19 H RasIDX protein antibody
    • p21ras antibody
    • Ras family small GTP binding protein H Ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • Transformation gene oncogene HAMSV antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • VH Ras antibody
    • vHa RAS antibody
    see all

Anti-GTPase HRAS antibody images

  • All lanes : Anti-GTPase HRAS antibody (ab97488) at 1/1000 dilution

    Lane 1 : HeLa whole cell lysate
    Lane 2 : HepG2 whole cell lysate
    Lane 3 : MOLT4 whole cell lysate

    Lysates/proteins at 30 µg/ml per lane.


    Predicted band size : 21 kDa
  • Immunohistochemical analysis of paraffin-embedded OVCAR3 xenograft, using ab97488 at 1/500 dilution.
  • Immunofluorescence analysis of paraformaldehyde-fixed HeLa cells, using ab97488 at 1/200 dilution. Lower image merged with DNA probe.

References for Anti-GTPase HRAS antibody (ab97488)

This product has been referenced in:
  • Nutter F  et al. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer 21:327-41 (2014). Read more (PubMed: 24413608) »
  • Wissner-Gross ZD  et al. Synchronous symmetry breaking in neurons with different neurite counts. PLoS One 8:e54905 (2013). WB ; Rat . Read more (PubMed: 23408951) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab97488.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"